3.945USD-2.83%Mkt Cap: 282.25M USDP/E: —Last update: 2026-05-26
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenose…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap282.25M USD
Enterprise Value117.60M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-137.06M USD
Revenue/Share—
Last Price3.945 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.66
PEG—
EV/EBITDA-0.84
EV/Revenue—
P/S—
P/B1.32
EPS (TTM)-1.74
EPS (Forward)-1.56
52W Range
1.13048% of range6.950
52W High6.950 USD
52W Low1.130 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-63.39%
ROA-47.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-125.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-25.98%
Net Debt-177.11M USD
Net Debt/EBITDA1.26
Balance Sheet
Debt/Equity0.17
Current Ratio6.19
Quick Ratio6.01
Book Value/Sh3.129 USD
Cash/Share2.975 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)6.500 USD
Target Range4.000 USD – 10.00 USD
# Analysts8
Ownership
Shares Out.71.19M
Float48.84M
Insiders22.44%
Institutions62.06%
Short Interest
Short Ratio1.4d
Short % Float9.65%
Short % Out.7.71%
Shares Short5.49M
Short (prev mo.)4.26M
Technical
SMA 503.648 (+8.2%)
SMA 2002.298 (+71.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.26M
Avg Vol (10d)1.23M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—